SL-172154

DRUG2 trials

Sponsors

Shattuck Labs, Inc.

Conditions

Acute Myeloid LeukemiaFallopian Tube CancerMyelodysplastic SyndromesOvarian CancerPrimary Peritoneal Carcinoma

Phase 1

Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer

CompletedNCT04406623

Shattuck Labs, Inc.Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma

Start: 2020-06-29End: 2023-02-02Updated: 2025-01-30

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

TerminatedNCT05275439

Shattuck Labs, Inc.Acute Myeloid Leukemia, Myelodysplastic Syndromes

Start: 2022-03-17End: 2025-02-06Updated: 2026-03-18

Related Papers

First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer

Journal for ImmunoTherapy of Cancer2025-01-019 citations

Phase 1 dose escalation study of SL-172154 (SIRPα-Fc-CD40L) in platinum-resistant ovarian cancer.

Journal of Clinical Oncology2023-06-019 citations

429 Phase 1 dose escalation study of the agonist redirected checkpoint, SL-172154 (SIRPα-Fc-CD40L) in subjects with platinum-resistant ovarian cancer

Regular and Young Investigator Award Abstracts2021-11-014 citations

3 Development of an integrated method to quantify receptor occupancy for agonist immunotherapeutics that stimulate target cells to migrate from the peripheral blood

Regular and Young Investigator Award Abstracts2021-11-011 citations